Login to Your Account

Abgenix Lays Off 15 Percent, Moves Research To Canada

By Randall Osborne

Thursday, June 30, 2005
Abgenix Inc.'s belt-tightening move that consolidates its research and preclinical activities into its Canadian facility in Burnaby, British Columbia, and lays off about 15 percent of its work force will give the firm more resources to direct toward panitumumab, the fully human monoclonal antibody for colorectal cancer partnered with Amgen Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription